Our results demonstrate that RANKL overexpression enhanced mammary-cancer-driven bone metastasis, while its inhibition by denosumab significantly reduced bone metastases, showing comparable efficacy to zoledronic acid. The gene discussed is TNFSF11; the disease is breast cancer.